Researchers discover SARS-CoV-2 inhibitors

A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus. The drug candidates are able to switch off the the key enzyme of the virus, the so-called main protease. The study is based on laboratory experiments. Extensive clinical trials […]

Continue Reading

Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies

Researchers from Cleveland Clinic’s Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models. According to new findings published in mBio, the vaccine produced potent neutralizing antibodies among preclinical models and also prevented infection and disease symptoms […]

Continue Reading

First COVID-19 COVAX vaccine doses administered in Africa

As the global rollout of COVAX vaccines accelerates, the first COVID-19 vaccination campaigns in Africa using COVAX doses began today in Ghana and CĂ´te d’Ivoire. These campaigns are the among the first to use doses provided by the COVAX Facility’s Gavi COVAX Advanced Market Commitment (AMC). The AMC is the COVAX Facility’s mechanism to provide […]

Continue Reading